Akebia Therapeutics (AKBA) Tops Q2 EPS by 1c

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $49 million versus the consensus estimate of $50.93 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• KeyBanc on National Fuel Gas (NFG): 'P&S Growth an Underappreciated Hedge to Weak Natural Gas Prices'
• Daré Bioscience gets $908K NIH grant for preterm birth program
• BetterLife Pharma names Charles Duncan as director and audit chair